offer
effect
treatment
respons
toward
hepat
b
viru
hbv
infect
eight
fdaapprov
drug
belong
two
class
current
avail
includ
two
interferon
alfa
drug
six
nucleo
ide
analog
hbeag
seroconvers
rate
gener
higher
hbeagposit
patient
receiv
interferon
therapi
nucleo
ide
analog
offer
better
treatment
respons
assess
pretreat
viral
factor
eg
hbv
genotyp
ontreat
viral
factor
eg
hbv
dna
hbsag
host
environment
factor
eg
patient
age
alt
recommend
initi
continu
hbv
therapi
nevertheless
singl
biomark
recogn
fulli
predict
treatment
respons
hbv
rna
recent
propos
new
biomark
assess
treatment
respons
hbv
rna
transcript
produc
directli
hbv
cccdna
may
monitor
progress
clearanc
hbv
cccdna
reservoir
potenti
predictor
treatment
respons
serum
hbv
rna
associ
intrahepat
cccdna
level
persist
viral
infect
rebound
instanc
earli
decreas
hbv
rna
effect
predict
hbeag
seroconvers
patient
receiv
either
lamivudin
tenofovir
responderenrich
subpopul
patient
treat
hbv
rna
recogn
sound
predictor
hbeag
seroconvers
univari
analys
alon
wherea
strength
unclear
larg
cohort
nonrespond
despit
encourag
find
mani
aspect
hbv
rna
remain
unclear
first
dynam
chang
hbv
rna
largescal
cohort
interferontr
patient
remain
poorli
understood
sinc
previou
studi
focus
mostli
nucleo
ide
analog
second
ambigu
hbv
rna
act
effect
predictor
interferon
respons
particularli
larg
cohort
nonrespond
third
offer
better
respons
remain
unclear
whether
hbv
rna
combin
known
hbv
biomark
could
offer
better
predict
perform
last
remain
unclear
whether
hbv
rna
could
predict
hbsag
loss
gener
consid
function
cure
signifi
favor
outcom
antivir
treatment
address
question
assess
hbv
rna
longitudin
cohort
hbeagposit
patient
randomli
receiv
base
largescal
cohort
find
support
hypothesi
even
earli
interferon
treatment
hbv
rna
strong
monitor
hbeag
seroconvers
despit
modest
role
predict
hbsag
loss
march
juli
total
hbeagposit
noncirrhot
patient
infect
hbv
monoinfect
least
month
treat
either
phase
multicent
random
control
clinic
trial
patient
randomli
assign
ratio
receiv
roch
switzerland
amoytop
biotechnolog
china
dose
week
treatmentfre
followup
week
fig
figur
approv
china
food
drug
administr
studi
perform
use
cohort
patient
complet
full
cours
random
trial
serum
sampl
week
measur
treatment
respons
trial
regist
chinadrugtrialsorg
id
clinicaltrialsgov
inclus
exclus
criteria
describ
clinic
protocol
see
supplementari
routin
physic
examin
biochem
hematolog
assess
conduct
week
hbv
rna
extract
patient
serum
sampl
use
nucleic
acid
extract
kit
sansur
biotech
inc
china
develop
base
magnet
bead
technolog
elut
hbv
rna
obtain
hbv
rna
extract
use
revers
transcript
primer
hbv
rnarac
hbv
rnaforward
hbv
rnarevers
hbv
rnaprob
see
supplementari
target
conserv
region
hbv
genom
obtain
literatur
armor
rna
intern
control
ad
sampl
lysi
absenc
dna
polymeras
cdna
primer
hbv
rna
revers
transcrib
cdna
temperatur
min
ad
dna
polymeras
cdna
primer
cdna
amplif
perform
activ
step
min
follow
twostep
cycl
cycl
cool
step
fluoresc
cdna
detect
measur
realtim
pcr
system
appli
detail
provid
supplementari
elecsi
test
roch
diagnost
gmbh
germani
use
measur
hbeag
antihb
hbsag
antihb
hbv
dna
quantifi
roch
diagnost
amplicor
hbv
test
version
roch
diagnost
germani
alt
assay
conduct
use
architect
clinic
chemistri
analyz
abbott
usa
ifcc
standard
enzym
determin
ncbi
hbv
genotyp
tool
appli
determin
hbv
genotyp
input
hbv
polymeras
sequenc
extract
convent
sanger
sequenc
detect
limit
hbv
rna
hbv
dna
hbeag
hbsag
copiesml
iuml
coi
cut
index
iuml
respect
valu
four
biomark
transform
prior
statist
analys
hbeag
seroconvers
also
call
serolog
respons
sr
defin
disappear
hbeag
accompani
gain
antihb
throughout
treatmentfre
followup
hbsag
loss
hl
indic
disappear
hbsag
four
major
statist
analys
perform
studi
first
explor
statist
differ
biomark
valu
patient
group
fisher
exact
test
test
conduct
categor
continu
variabl
respect
logist
regress
perform
estim
odd
ratio
confid
interv
ci
second
quantifi
correl
continu
biomark
use
spearman
correl
coeffici
third
logist
linear
regress
analys
reveal
factor
significantli
associ
treatment
respons
predict
perform
measur
auc
analys
hbv
biomark
valu
detect
limit
replac
detect
limit
fourth
standard
softwar
cutoff
finder
appli
optim
biomark
cutoff
standard
bootstrap
resampl
method
appli
gener
random
dataset
fivefold
crossvalid
avoid
overestim
robust
biomark
cutoff
confirm
bootstrap
resampl
crossvalid
sixth
predictor
import
estim
measur
random
forest
classif
decis
tree
curvatur
test
split
predictor
surrog
split
handl
miss
valu
sinc
miss
data
appear
dataset
analys
use
avail
case
variabl
interest
known
approach
call
pairwis
delet
analys
conduct
use
matlab
entir
cohort
consist
male
femal
predomin
infect
hbv
genotyp
c
n
follow
genotyp
b
n
n
bc
recombin
n
baselin
mean
standard
error
patient
age
bodi
weight
alt
year
kg
iuml
respect
tabl
moreov
baselin
valu
hbv
rna
hbv
dna
hbsag
hbeag
copiesml
iuml
iuml
coi
respect
distribut
hbv
biomark
shown
fig
hbeag
seroconvers
hbsag
loss
week
observ
patient
respect
hbeag
seroconvers
found
patient
similar
patient
receiv
p
valu
respons
hbsag
loss
also
show
differ
arm
p
valu
neither
host
gender
age
bodi
mass
index
weight
alanin
transaminas
viral
biomark
hbv
rna
hbv
dna
hbeag
hbsag
genotyp
show
signific
differ
arm
tabl
subsequ
analys
patient
achiev
serolog
respons
hbsag
loss
sort
sr
hl
group
respect
first
onesampl
test
show
hbv
rna
individu
sampl
timepoint
follow
normal
distribut
second
nonparametr
spearman
correl
analys
reveal
posit
coeffici
pairwis
correl
hbv
rna
hbeag
hbsag
hbv
dna
third
hbv
rna
strongli
correl
hbeag
hbv
dna
p
valu
correl
coeffici
hbsag
weakest
week
figur
similar
pattern
also
observ
arm
overal
strong
correl
hbv
rna
hbeag
support
hbv
rna
might
potenti
predictor
hbeag
seroconvers
three
independ
analys
perform
explor
hbv
rna
serv
favor
monitor
foretel
interferon
respons
first
hbv
rna
share
decreas
pattern
similar
hbeag
sr
group
harbor
patient
hbeag
seroconvers
fig
hbv
rna
decreas
rapidli
patient
hbsag
loss
patient
without
hbsag
loss
fig
week
signific
differ
hbv
rna
decreas
hbeag
decreas
undetect
sr
group
p
valu
wherea
pairwis
comparison
factor
exhibit
signific
differ
p
valu
fig
patient
show
declin
hbv
rna
week
achiev
hbsag
loss
n
hbeag
seroconvers
n
two
hl
patient
sr
patient
show
declin
hbv
rna
week
moreov
hbv
rna
stabil
treatment
cessat
week
like
maintain
sr
nonsr
patient
p
valu
second
univari
multivari
regress
analys
reveal
hbv
rna
effect
predictor
hbeag
seroconvers
tabl
despit
ineffect
estim
hbsag
loss
tabl
week
univari
regress
analys
consist
reveal
hbv
rna
factor
hbv
dna
hbsag
hbeag
hbv
genotyp
age
weight
significantli
associ
hbeag
seroconvers
p
valu
wherea
gender
type
show
differ
multivari
analys
show
hbv
rna
plu
hbeag
patient
age
remain
signific
week
tabl
regard
predict
hbsag
loss
hbv
rna
baselin
week
signific
predictor
univari
analys
signific
disappear
multivari
analys
probabl
due
strong
predict
role
hbsag
week
tabl
furthermor
predictor
import
estim
independ
reveal
signific
hbv
rna
week
sr
predict
fig
wherea
hbv
rna
show
advantag
compar
hbsag
estim
hbsag
loss
fig
third
auc
analys
reveal
advantag
hbv
rna
especi
week
predict
hbeag
seroconvers
sr
predict
auc
valu
hbv
rna
gradual
increas
baselin
auc
week
auc
week
auc
week
auc
see
fig
signific
increas
observ
baselin
week
p
valu
moreov
hbv
rna
show
advantag
hbeag
p
valu
week
perform
also
superior
hbv
dna
hbsag
week
p
valu
howev
compar
hbsag
hbv
rna
modest
predictor
hbsag
loss
fig
identifi
simpl
cutoff
clinic
use
hbv
biomark
cutoff
optim
forecast
hbeag
seroconvers
baselin
cutoff
hbv
rna
copiesml
show
modest
perform
accuraci
compar
hbsag
hbv
dna
compar
baselin
result
optim
cutoff
hbv
rna
copiesml
week
offer
signific
increas
accuraci
neg
predict
valu
posit
predict
valu
former
two
measur
show
best
perform
compar
hbeag
hbsag
hbv
dna
cutoff
tabl
neg
predict
valu
use
indic
discontinu
interferon
treatment
week
hbv
rna
copiesml
observ
patient
fail
achiev
hbeag
seroconvers
cutoff
also
show
best
perform
accuraci
posit
predict
valu
compar
hbv
dna
hbsag
hbeag
cutoff
week
tabl
hypothes
multipl
factor
indic
multivari
regress
analys
may
increas
predict
perform
albeit
interferon
offer
hbeag
seroconvers
clinic
studi
tabl
hypothesi
support
dual
combin
ad
hbv
rna
individu
tradit
hbv
biomark
significantli
increas
auc
perform
p
valu
fig
next
screen
combin
avail
factor
patient
age
alt
hbv
genotyp
hbv
rna
hbv
dna
hbsag
hbeag
identifi
best
combin
achiev
highest
rate
sr
minimum
variabl
size
combin
four
factor
hbv
rna
copiesml
patient
age
genotyp
b
hbeag
coi
offer
best
perform
stepwis
combin
gradual
increas
accuraci
predict
hbeag
seroconvers
fig
stepwis
combin
hbv
rna
plu
genotyp
b
patient
age
hbeag
auc
valu
significantli
increas
p
valu
fig
illustr
decis
tree
model
fig
fourfactor
combin
offer
superior
perform
accuraci
true
neg
rate
forecast
hbeag
seroconvers
even
earli
period
week
studi
reveal
signific
role
serum
hbv
rna
forecast
treatment
respons
hbeagposit
patient
largest
cohort
studi
hbv
rna
report
far
studi
reveal
three
major
find
support
use
hbv
rna
earli
ontreat
factor
estim
respons
first
hbv
rna
posit
correl
tradit
hbv
biomark
also
act
strong
predictor
hbeag
seroconvers
modest
predictor
hbsag
loss
second
hbv
rna
week
earli
predictor
optim
cutoff
approxim
copiesml
effect
forecast
hbeag
seroconvers
support
hypothesi
suppress
hbv
rna
low
level
may
lead
better
treatment
outcom
third
hbv
rna
plu
tradit
factor
patient
age
hbv
genotyp
hbeag
consider
forecast
respons
even
earli
period
week
earli
predict
treatment
respons
great
clinic
valu
treatment
usual
expens
caus
sever
advers
event
long
term
serum
hbv
rna
previous
report
potenti
biomark
estim
treatment
outcom
hbv
polymeras
inhibitor
small
cohort
responderenrich
patient
studi
hbv
rna
evalu
use
random
phase
cohort
hbeagposit
patient
univari
multivari
regress
analys
consist
reveal
predict
valu
hbv
rna
sr
predict
week
tabl
moreov
observ
hbv
rna
posit
correl
hbeag
hbv
dna
hbsag
sampl
point
agreement
literatur
result
hbv
rna
decreas
faster
hbv
dna
hbsag
earli
treatment
period
wherea
decreas
pattern
sr
patient
similar
hbeag
support
potenti
predict
hbeag
seroconvers
fig
contrast
hbv
rna
modest
predictor
hbsag
loss
analys
agreement
recent
review
highlight
hbsag
key
predictor
hbsag
loss
biomark
seem
less
effect
kinet
hbv
rna
may
vari
due
differ
therapi
treatment
durat
declin
serum
hbv
rna
commonli
observ
treatment
interferon
andor
nucleo
ide
analog
agreement
previou
find
nucleo
ide
analog
studi
reveal
effect
hbv
rna
week
predict
hbeag
seroconvers
interferon
treatment
monitor
hbv
rna
dynam
week
found
fast
decreas
hbv
rna
week
baselin
hbv
rna
sound
predictor
hbeag
seroconvers
recent
studi
howev
report
hbv
rna
outperform
hbeag
baselin
responseenrich
patient
treat
disagr
might
due
cohort
includ
responseenrich
patient
n
sr
screen
two
differ
clinic
trial
n
sr
n
sr
despit
result
literatur
result
support
low
level
fast
decreas
hbv
rna
like
associ
treatment
success
even
earli
period
hbv
biomark
cutoff
commonli
use
monitor
treatment
respons
clinic
practic
base
cohort
patient
cutoff
hbv
rna
optim
copiesml
effect
predict
hbeag
seroconvers
favor
perform
hbv
rna
cutoff
also
highlight
better
accuraci
compar
hbv
dna
hbsag
hbeag
cutoff
tabl
furthermor
earli
discontinu
interferon
treatment
could
consid
hbeagposit
patient
show
hbv
rna
copiesml
week
patient
unabl
achiev
hbeag
seroconvers
addit
predict
perform
individu
biomark
studi
prove
multivari
combin
hbv
rna
plu
hbeag
patient
age
genotyp
b
offer
high
level
posit
predict
valu
specif
provid
clear
evid
hbv
rna
effect
integr
tradit
biomark
monitor
treatment
respons
limit
studi
analyz
phase
clinic
trial
chines
patient
mainli
infect
hbv
genotyp
b
c
futur
studi
need
recruit
patient
infect
hbv
genotyp
studi
focus
interferon
treatment
hbeagposit
noncirrhot
patient
futur
analys
need
clarifi
hbv
rna
hbeagneg
patient
associ
hbv
rna
cirrhosi
hepatocellular
carcinoma
fulllength
hbv
rna
could
quantifi
use
primer
taken
previou
public
studi
need
confirm
whether
encapsul
polyadenyl
serum
hbv
rna
equal
fulllength
rna
contain
truncat
rna
speci
due
limit
patient
hbsag
loss
cohort
associ
hbv
rna
hbsag
loss
evalu
followup
studi
overal
find
suggest
serum
hbv
rna
may
serv
earli
ontreat
predictor
hbv
cccdna
activ
reveal
treatment
success
interferon
therapi
although
standard
hbv
rna
toolkit
yet
develop
clinic
use
preliminari
clinic
signific
hbv
rna
support
largescal
studi
discoveri
hbv
rna
effect
earli
biomark
may
lead
better
manag
interferon
therapi
hbvinfect
patient
drive
clinic
use
hbv
rna
